secwatch / observer

8-K filed August 9, 2023, 7:59 PM ET ticker TNYA CIK 0001858848

earnings confidence high sentiment neutral materiality 0.55

Tenaya Q2 net loss $33.3M; TN-201 first patient dosing on track for Q3 2023

Tenaya Therapeutics, Inc.

2023-Q2 EPS reported -$0.89

Cash and investments $151.6M; runway into first half 2025.
R&D expense $26.5M; G&A expense $8.6M; net loss $0.45/share.
First patient in MyPeak-1 Phase 1b trial of TN-201 expected in Q3 2023.
Data from TN-301 Phase 1 trial accepted for HFSA October 2023.
IND for TN-401 PKP2 gene therapy planned for H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tenaya Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $33.3 million, EPS $0.45 per share.

Period: the second quarter ended June 30, 2023
Net income: $33.3 million
EPS: $0.45 per share
Result: reported results

Exact text from the filing

Net loss for the quarter ended June 30, 2023, was $33.3 million, or $0.45 per share.

View on SEC.gov

Browse all earnings releases →

Tenaya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-040628

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.